Scholarlink

Purpose <p>RAS mutations play a critical role in the pathogenesis and progression of colorectal cancer. This study aimed to evaluate the clinical and pathological characteristics associated with RAS mutation status and to investigate its prognostic value in patients with metastatic colorectal cancer.</p> Methods <p>This retrospective study included 446 adult patients with metastatic colorectal cancer followed at Dokuz Eylul University Medical Oncology Department between 2010 and 2016, all of whom had available RAS mutation data and complete clinical records.</p> Results <p>RAS mutations were identified in 44.8% of patients, predominantly KRAS codon 12 mutations. Early-stage disease and absence of metastasis at diagnosis were more common in the RAS wild-type (WT) group (<i>p</i> &lt; 0.001). Lung metastases occurred more frequently in RAS-mutant cases (<i>p</i> = 0.006). No significant difference in overall survival (OS) was observed between RAS-mutant and WT groups (53.6 vs. 52.5 months; <i>p</i> &gt; 0.05). Anti-VEGF therapy conferred a modest OS benefit in RAS-mutant patients, whereas anti-EGFR therapy showed no effect. Among KRAS-mutant subtypes, codon 61 mutations were associated with the poorest OS.</p> Conclusion <p>RAS mutation status may provide insight into metastatic patterns and disease stage in patients with metastatic colorectal cancer. However, its impact on overall survival remains inconclusive. Further prospective studies are needed to clarify its prognostic value.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical and prognostic implications of RAS mutations in metastatic colorectal cancer

  • 期刊论文

  • 发表日期：

    2025年12月19日

查看全文
  • Evrim Ataca,
  • Merve Keskinkilic,
  • Sulen Sarioglu,
  • Yasemin Basbinar,
  • Tugba Yavuzsen

摘要

Purpose

RAS mutations play a critical role in the pathogenesis and progression of colorectal cancer. This study aimed to evaluate the clinical and pathological characteristics associated with RAS mutation status and to investigate its prognostic value in patients with metastatic colorectal cancer.

Methods

This retrospective study included 446 adult patients with metastatic colorectal cancer followed at Dokuz Eylul University Medical Oncology Department between 2010 and 2016, all of whom had available RAS mutation data and complete clinical records.

Results

RAS mutations were identified in 44.8% of patients, predominantly KRAS codon 12 mutations. Early-stage disease and absence of metastasis at diagnosis were more common in the RAS wild-type (WT) group (p < 0.001). Lung metastases occurred more frequently in RAS-mutant cases (p = 0.006). No significant difference in overall survival (OS) was observed between RAS-mutant and WT groups (53.6 vs. 52.5 months; p > 0.05). Anti-VEGF therapy conferred a modest OS benefit in RAS-mutant patients, whereas anti-EGFR therapy showed no effect. Among KRAS-mutant subtypes, codon 61 mutations were associated with the poorest OS.

Conclusion

RAS mutation status may provide insight into metastatic patterns and disease stage in patients with metastatic colorectal cancer. However, its impact on overall survival remains inconclusive. Further prospective studies are needed to clarify its prognostic value.